Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
Continuous glucose monitors — the tiny sensors once reserved for people with diabetes — are now appearing on the arms of ...
We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.’s share was trading at $65.41 as of October 15th.
Walmart will become the first U.S. retailer to sell Abbott Laboratories' over-the-counter continuous glucose monitor Lingo in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback